Abstract: The present disclosure relates to one or more modified avian-virus based agents, therapies, treatments, and methods of use of the modified avian-virus based agents and/or therapies and/or treatments for cancer. The disclosure also provides for methods of generating modified avian-virus based agents.
Type:
Application
Filed:
December 14, 2018
Publication date:
June 18, 2020
Inventors:
Robert KOZAK, Byram BRIDLE, Eva NAGY, Bradley THOMPSON
Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
Type:
Application
Filed:
October 16, 2017
Publication date:
March 8, 2018
Inventors:
Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
Abstract: The present disclosure relates to one or more modified avian-virus based agents, therapies, treatments, and methods of use of the modified avian-virus based agents and/or therapies and/or treatments for cancer. The disclosure also provides for methods of generating modified avian-virus based agents.
Type:
Grant
Filed:
December 14, 2018
Date of Patent:
November 10, 2020
Assignee:
ARV Pharma Inc.
Inventors:
Robert Kozak, Byram Bridle, Eva Nagy, Bradley Thompson
Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
Type:
Application
Filed:
March 9, 2012
Publication date:
July 10, 2014
Inventors:
Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
Type:
Grant
Filed:
March 9, 2012
Date of Patent:
November 21, 2017
Assignee:
Turnstone Limited Partnership
Inventors:
Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
Abstract: An engineered Newcastle Disease Virus (NDV) vector is provided. In particular, the present disclosure provides methods of treating or preventing a disease such as cancer, or an infectious disease, or methods for eliciting an immune response, with the engineered NDV vector. The engineered NDV vector provided herein is useful as an immunogenic composition, an oncolytic agent, or a vaccine.
Type:
Application
Filed:
June 3, 2022
Publication date:
December 15, 2022
Inventors:
Sarah Wootton, Leonardo Susta, Byram Bridle, Pierre Major, Lisa Santry, Yanlong Pei
Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.
Type:
Application
Filed:
March 16, 2010
Publication date:
January 19, 2012
Inventors:
Brian Lichty, Byram Bridle, Yonghong Wan, Jonathan Bramson
Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumor antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.
Type:
Grant
Filed:
March 16, 2010
Date of Patent:
July 18, 2017
Assignee:
Turnstone Limited Partnership
Inventors:
Brian Lichty, Byram Bridle, Yonghong Wan, Jonathan Bramson
Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.
Type:
Grant
Filed:
June 22, 2017
Date of Patent:
February 23, 2021
Assignee:
Turnstone Limited Partnership
Inventors:
Brian Lichty, Byram Bridle, Yonghong Wan, Jonathan Bramson